<br>        Inclusion Criteria:<br><br>        Written informed consent Male and female patients 18 years or older (at the time of the<br>        screening visit). Patients must weigh at least 50 kg (110 lb) and no more than 200 kg (440<br>        lb) to participate in the study.<br><br>        Able to communicate well with the investigator, to understand and comply with the<br>        requirements of the study.<br><br>        Adequate liver biopsy sample for evaluation by Central Reader. Presence of NASH as<br>        demonstrated by histologic evidence based on liver biopsy - NASH with fibrosis stage F2/F3,<br>        demonstrated on liver biopsy during the screening period. Alternatively, a historical<br>        biopsy can be used if performed within 6 months prior to screening.<br><br>        Exclusion Criteria:<br><br>        Use of other investigational drugs within 5 half-lives of enrollment or within 30 days<br>        whichever is longer.<br><br>        History of hypersensitivity to any of the study drugs or its excipients or to drugs of<br>        similar chemical classes.<br><br>        Previous exposure to elafibranor, CVC, tropifexor, obeticholic acid (OCA), LMB763 or other<br>        FXR agonist.<br><br>        Participated in a clinical trial and treated with any investigational product being<br>        evaluated for the treatment of liver fibrosis or NASH in the 6 months before screening.<br><br>        Patients taking medications prohibited by the protocol. History of treated or untreated<br>        malignancy of any organ system, other than localized basal cell carcinoma of the skin or<br>        treated cervical intraepithelial neoplasia, within the past 5 years, regardless of whether<br>        there is evidence of local recurrence or metastases .<br><br>        Pregnant or nursing (lactating) women. Women of child-bearing potential. Current or history<br>        of significant alcohol consumption for a period of more than 3 consecutive months within 1<br>        year prior to screening (significant alcohol consumption is defined as more than 20 g/day<br>        in females and more than 30 g/day in males, on average) and/or a score on the modified<br>        AUDIT questionnaire = 8.<br><br>        Inability to reliably quantify alcohol consumption. History or evidence of ongoing drug<br>        abuse, within the last 6 months prior to randomization.<br><br>        Prior or planned (during the study) bariatric surgery. Uncontrolled diabetes defined as<br>        HbA1c = 9% at screening Clinical evidence of hepatic decompensation or severe liver<br>        impairment. Previous diagnosis of other forms of chronic liver disease. Calculated eGFR<br>        less than 60 mL/min (using the MDRD formula). History of biliary diversion History of liver<br>        transplantation or planned liver transplant. Known positivity for HIV. History or current<br>        diagnosis of ECG abnormalities indicating significant risk of safety for the patient to<br>        participate.<br><br>        History of inflammatory bowel disease. Patients who are not candidates for liver biopsy.<br>        Presence of cirrhosis on liver biopsy (F4 by NASH CRN System) or medical history Patients<br>        with an abnormal platelet count (referring to reference ranges from the central lab).<br>